相关实验视频
Updated: Jun 24, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.6K
孕期糖尿病中的胰岛素降解剂:证据和前景
Georgios S Papaetis1,2, Konstantinos C Mikellidis3
1K.M.P THERAPIS Paphos Medical Center, Internal Medicine and Diabetes Clinic, Paphos, Cyprus.
概括
在孕期糖尿病中实现严格的血糖控制对于减少不良妊娠结果至关重要. 胰岛素降糖提供可预测的葡萄糖水平,最大限度地减少母亲的低血糖发作,改善胎儿和母亲的健康.
科学领域:
- 内分泌学 在内分泌学.
- 生殖医学 生殖医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 孕期糖尿病增加了对胚胎/胎儿不良结果的风险.
- 在怀孕前和怀孕期间严格控制血糖是非常重要的.
- 孕产妇低血糖是最佳血糖控制的重要障碍.
研究的目的:
- 审查目前关于在孕期糖尿病中使用胰岛素降解剂的证据.
- 评估胰岛素降级剂在这个患者群体中的潜在作用.
主要方法:
- 对现有的科学文献进行全面的审查.
- 分析胰岛素 degludec 的药理动力学和药理动力学特性.
- 检查临床试验数据和观察性研究.
主要成果:
- 胰岛素降解剂是一种超长效的胰岛素,其半衰期超过25小时.
- 它提供稳定,可预测的胰岛素度,变化最小.
- 它具有较低的线粒生成/代谢功效比,这表明它具有良好的安全性.
结论:
- 胰岛素 degludec 显示出改善孕期糖尿病的血糖控制的潜力.
- 其可预测的形状可能有助于减轻低血糖事件,改善孕产妇和胎儿的结果.
- 需要进一步的研究,以充分确定其在管理孕期糖尿病中的作用.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Pathophysiology of Diabetes
920
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
920
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Glucagon-like Receptor Agonists
316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189

